GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Access Bio Inc (XKRX:950130) » Definitions » Current Ratio

Access Bio (XKRX:950130) Current Ratio : 10.11 (As of Mar. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Access Bio Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Access Bio's current ratio for the quarter that ended in Mar. 2024 was 10.11.

Access Bio has a current ratio of 10.11. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Access Bio's Current Ratio or its related term are showing as below:

XKRX:950130' s Current Ratio Range Over the Past 10 Years
Min: 0.75   Med: 3.1   Max: 33.23
Current: 10.11

During the past 12 years, Access Bio's highest Current Ratio was 33.23. The lowest was 0.75. And the median was 3.10.

XKRX:950130's Current Ratio is ranked better than
94.85% of 233 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.13 vs XKRX:950130: 10.11

Access Bio Current Ratio Historical Data

The historical data trend for Access Bio's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Access Bio Current Ratio Chart

Access Bio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.46 1.61 2.37 3.65 9.51

Access Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.08 10.76 11.18 9.51 10.11

Competitive Comparison of Access Bio's Current Ratio

For the Diagnostics & Research subindustry, Access Bio's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Access Bio's Current Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Access Bio's Current Ratio distribution charts can be found below:

* The bar in red indicates where Access Bio's Current Ratio falls into.



Access Bio Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Access Bio's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=418432.916/44016.853
=9.51

Access Bio's Current Ratio for the quarter that ended in Mar. 2024 is calculated as

Current Ratio (Q: Mar. 2024 )=Total Current Assets (Q: Mar. 2024 )/Total Current Liabilities (Q: Mar. 2024 )
=438362.894/43367.145
=10.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Access Bio  (XKRX:950130) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Access Bio Current Ratio Related Terms

Thank you for viewing the detailed overview of Access Bio's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Access Bio (XKRX:950130) Business Description

Traded in Other Exchanges
N/A
Address
65 Clyde Road, Suite A, Somerset, NJ, USA, 08873
Access Bio Inc is a United States based bio company engaged in the research, development, and manufacturing of in vitro rapid diagnostic tests, biosensor, and molecular diagnostic products. The products are for the prevention and early diagnosis of infectious diseases. The company's core in vitro-diagnostic technology includes immunochemical, biochemical and molecular products. The company offers products for Rapid Diagnostic Tests including CareStart G6PD RDT, CareStart Malaria, CareStart Dengue Combo, and CareStart Scrub Typhus IgM; Biosensors product includes CareStart G6PD Biosensor, and Molecular Diagnostics products include CareStart HPV and CareStart CAH.

Access Bio (XKRX:950130) Headlines

No Headlines